Skip to main content
SpringerLink
Log in

Epidemiology and Diagnosis of Neuroendocrine Tumors

  • Chapter
  • First Online:
Neuroendocrine Tumors

  • 558 Accesses

Abstract

Neuroendocrine tumors (NETs) constitute a group of malignancies arising from neuroendocrine precursor cells that can arise anywhere in the body. The incidence and prevalence of NETs have steadily increased over the past four decades. Given their heterogeneous and often indolent presentation, the initial diagnosis of NETs can be challenging. In this chapter, we provide a comprehensive overview on the epidemiology and diagnosis of NETs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Choti MA, Bobiak S, Strosberg JR, et al. Prevalence of functional tumors in neuroendocrine carcinoma: an analysis from the NCCN NET database. J Clin Oncol. 2012;30(15_suppl):4126.

    Article  Google Scholar 

  3. Broder MS, Cai B, Chang E, Neary MP. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database. BMC Pulm Med. 2018;18(1):135.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Smith-Bindman R, Kwan ML, Marlow EC, et al. Trends in use of medical imaging in US health care systems and in Ontario, Canada, 2000-2016. JAMA. 2019;322(9):843–56.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Shen C, Gu D, Zhou S, et al. Racial differences in the incidence and survival of patients with neuroendocrine tumors. Pancreas. 2019;48(10):1373–9.

    Article  PubMed  Google Scholar 

  6. Obendorfer. Karzinoide tumoren des dunndarms. Frankf Z Pathol. 1907;1:425–9.

    Google Scholar 

  7. Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013;20(2):187–96.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Verbeek WH, Korse CM, Tesselaar ME. GEP-NETs UPDATE: secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers. Eur J Endocrinol. 2016;174(1):R1–7.

    Article  CAS  PubMed  Google Scholar 

  9. Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res. 1999;18(2):133–41.

    CAS  PubMed  Google Scholar 

  10. Palaniswamy C, Frishman WH, Aronow WS. Carcinoid heart disease. Cardiol Rev. 2012;20(4):167–76.

    Article  PubMed  Google Scholar 

  11. Feldman JM, O’Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med. 1986;81(6B):41–8.

    Article  CAS  PubMed  Google Scholar 

  12. Tellez MR, Mamikunian G, O'Dorisio TM, Vinik AI, Woltering EA. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas. 2013;42(3):405–10.

    Article  CAS  PubMed  Google Scholar 

  13. Carling RS, Degg TJ, Allen KR, Bax ND, Barth JH. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem 2002;39(Pt 6):577–582.

    Google Scholar 

  14. Yang X, Yang Y, Li Z, et al. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0124884.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–92.

    Article  CAS  PubMed  Google Scholar 

  16. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999;17(2):615–30.

    Article  CAS  PubMed  Google Scholar 

  17. Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. World J Gastroenterol. 2012;18(39):5495–503.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Feng J, Petersen CD, Coy DH, et al. Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion. Proc Natl Acad Sci U S A. 2010;107(41):17791–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Poitras P, Gingras MH, Rehfeld JF. Secretin stimulation test for gastrin release in Zollinger-Ellison syndrome: to do or not to do? Pancreas. 2013;42(6):903–4.

    Article  PubMed  Google Scholar 

  20. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14(12):3492–500.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Wu SL, Bai JG, Xu J, Ma QY, Wu Z. Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor. World J Surg Oncol. 2014;12:220.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Castro PG, de Leon AM, Trancon JG, et al. Glucagonoma syndrome: a case report. J Med Case Rep. 2011;5:402.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the glucagonoma syndrome – cumulative experience with an elusive endocrine tumour. Clin Endocrinol. 2011;74(5):593–8.

    Article  Google Scholar 

  24. Kimbara S, Fujiwara Y, Toyoda M, et al. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. Clin J Gastroenterol. 2014;7(3):255–9.

    Article  PubMed  Google Scholar 

  25. Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26(6):791–802.

    Article  CAS  PubMed  Google Scholar 

  26. La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40(1):30–40.

    Article  PubMed  Google Scholar 

  27. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma – incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711–9.

    Article  PubMed  Google Scholar 

  28. Nozieres C, Chardon L, Goichot B, et al. Neuroendocrine tumors producing calcitonin: characteristics, prognosis and potential interest of calcitonin monitoring during follow-up. Eur J Endocrinol. 2016;174(3):335–41.

    Article  CAS  PubMed  Google Scholar 

  29. Adrian TE, Uttenthal LO, Williams SJ, Bloom SR. Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors. N Engl J Med. 1986;315(5):287–91.

    Article  CAS  PubMed  Google Scholar 

  30. Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Investig. 2004;27(1):6–11.

    Article  CAS  Google Scholar 

  31. Walter T, Chardon L, Chopin-laly X, et al. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer. 2012;48(12):1766–73.

    Article  CAS  PubMed  Google Scholar 

  32. Deppen SA, Liu E, Blume JD, et al. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med. 2016;57(5):708–14.

    Article  CAS  PubMed  Google Scholar 

  33. Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105(3):212–44.

    Article  CAS  PubMed  Google Scholar 

  34. Ayati N, Lee ST, Zakavi R, et al. Long-acting somatostatin analog therapy differentially alters (68)Ga-DOTATATE uptake in normal tissues compared with primary tumors and metastatic lesions. J Nucl Med. 2018;59(2):223–7.

    Article  CAS  PubMed  Google Scholar 

  35. Bhattacharyya S, Toumpanakis C, Chilkunda D, Caplin ME, Davar J. Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol. 2011;107(8):1221–6.

    Article  PubMed  Google Scholar 

  36. Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol. 2009;27(26):4293–9.

    Article  CAS  PubMed  Google Scholar 

  37. Anlauf M, Garbrecht N, Bauersfeld J, et al. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch. 2007;451(Suppl 1):S29–38.

    Article  PubMed  Google Scholar 

  38. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.

    Article  CAS  PubMed  Google Scholar 

  39. Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol. 2006;30(5):560–74.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ohio State University Wexner Medical Center, Columbus, OH, USA

    Vineeth Sukrithan & Bhavana Konda

Authors
  1. Vineeth Sukrithan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhavana Konda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vineeth Sukrithan .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Jordan M. Cloyd

  2. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

    Timothy M. Pawlik

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sukrithan, V., Konda, B. (2021). Epidemiology and Diagnosis of Neuroendocrine Tumors. In: Cloyd, J.M., Pawlik, T.M. (eds) Neuroendocrine Tumors. Springer, Cham. https://doi.org/10.1007/978-3-030-62241-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62241-1_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62240-4

  • Online ISBN: 978-3-030-62241-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation